
The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.

Your AI-Trained Oncology Knowledge Connection!



The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.

A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.